edoc

Therapeutic targeting of CD146/MCAM reduces bone metastasis in prostate cancer

Zoni, Eugenio and Astrologo, Letizia and Ng, Charlotte K. Y. and Piscuoglio, Salvatore and Melsen, Janine and Grosjean, Joel and Klima, Irena and Chen, Lanpeng and Snaar-Jagalska, Ewa B. and Flanagan, Kenneth and van der Pluijm, Gabri and Kloen, Peter and Cecchini, Marco G. and Kruithof-de-Julio, Marianna and Thalmann, George N.. (2019) Therapeutic targeting of CD146/MCAM reduces bone metastasis in prostate cancer. Molecular cancer research. Epubaheadofrint].

[img] PDF - Accepted Version
Restricted to Repository staff only until 1 June 2020.

4Mb

Official URL: https://edoc.unibas.ch/69483/

Downloads: Statistics Overview

Abstract

Prostate Cancer (PCa) is the most common cancer and the second leading cause of cancer-related death in males. When PCa acquires castration resistance, incurable metastases, primarily in the bone, occur. The aim of this study is to test the applicability of targeting MCAM (CD146) with a monoclonal antibody for the treatment of lytic PCa bone metastasis. We evaluated the effect of targeting MCAM using in vivo preclinical bone metastasis models and an in vitro bone niche co-culture system. We utilized FACS, cell proliferation assays, and gene expression profiling to study the phenotype and function of MCAM knockdown in vitro and in vivo. To demonstrate the impact of MCAM targeting and therapeutic applicability, we employed an anti-MCAM monoclonal antibody in vivo. MCAM is elevated in PCa metastases resistant to androgen-ablation. Treatment with Dihydrotestosterone showed MCAM upregulation upon castration. We investigated the function of MCAM in a direct co-culture model of human PCa cells with human osteoblasts and found that there is reduced influence of human osteoblasts on human PCa cells in which MCAM has been knocked down. Furthermore, we observed strongly reduced formation of osteolytic lesions upon bone-inoculation of MCAM-depleted human PCa cells in animal model of PCa bone metastasis. This phenotype is supported by RNA Sequencing analysis. Importantly, in vivo administration of an anti-MCAM human monoclonal antibody reduced tumor growth and lytic lesions. These results highlight the functional role for MCAM in the development of lytic-bone metastasis and suggest that MCAM is a potential therapeutic target in PCa bone metastasis. Implications: This study highlights the functional application of an anti-MCAM monoclonal antibody to target prostate cancer bone metastasis.
Faculties and Departments:03 Faculty of Medicine
03 Faculty of Medicine > Bereich Querschnittsfächer (Klinik) > Pathologie USB
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Querschnittsfächer (Klinik) > Pathologie USB
03 Faculty of Medicine > Departement Biomedizin
UniBasel Contributors:Piscuoglio, Salvatore
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:American Association for Cancer Research
ISSN:1541-7786
e-ISSN:1557-3125
Note:Publication type according to Uni Basel Research Database: Journal article
Language:English
Identification Number:
Last Modified:05 Jun 2019 13:49
Deposited On:05 Jun 2019 13:49

Repository Staff Only: item control page